Safety of HPV vaccines in the age of nonavalent vaccination

Quattrone, Filippo; Canale, A; Filippetti, Elisa; Tulipani, Alberto; Lopalco, Pietro Luigi

doi:10.23736/s0026-4946.17.05147-7

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, healthcare providers were considered the primary and most trusted source of health and vaccine information for the public. According to available data, rumors about vaccine safety had been one of the principal obstacles for the acceptance of HPV vaccination by the public [23]. Therefore, it is positive that the HPVv is very important for Polish gynecologists: 99.5% found this vaccination relevant and almost 94% claimed to talk with their patients about the possibility of immunization.…”

Section: Discussionmentioning

confidence: 99%

A survey of knowledge, attitudes and awareness of the HPV and HPV vaccine among obstetricians and gynecologists across Poland

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A survey of knowledge, attitudes and awareness of the HPV and HPV vaccine among obstetricians and gynecologists across Poland

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Most recently in 2014, the nine-valent vaccine against HPV (Gardasil 9 ® ) was released. The HPV vaccine has been incorporated into the Greek national vaccination program since 2008 and since 2017 it is administered for free only until the age of 16 years of age [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Health Education on Adolescents’ Awareness of HPV Infections and Attitudes towards HPV Vaccination in Greece

Thanasas

Lavranos

Gkogkou

et al. 2022

IJERPH

View full text Add to dashboard Cite

Background: The purpose of this paper is to evaluate the role of health education among young adolescents, regarding their level of knowledge about the HPV and the acceptance of the HPV vaccination, with the aim of increasing vaccination coverage, in Trikala city, mainland of Greece. Methods: This study included high school students from all public and private schools of Trikala city. Questionnaires related to knowledge regarding the HPV infection and HPV vaccination were administered in three phases. In the first phase of the study, the questionnaires were completed by the entire study population. During the second and third phases, the completion of the questionnaires concerned only the population that received the intervention (interactive seminars). The second and third phase questionnaires were completed immediately after the interactive seminar and three months later, respectively. The statistical analysis of the results was performed using IBM SPSS 20.0 statistical program. Results: A total of 434 female students completed the questionnaire (response rate 76.26%). Most participants (66.6%) were females. The questionnaires evaluated the respondents’ awareness of the HPV infection. The results show that the percentage of the participants who stated that they “do not know” what HPV is decreased from 44.4% (first phase), to 1.6% (second phase), and 8.1% (third phase). Similarly, the willingness to accept the HPV vaccine increased from 71% (first phase), to 89.1% (second phase), and 83.5% (third phase). Conclusions: The present study shows that targeted interactive informational interventions in the school environment leads to a statistically significant increase in both the level of knowledge about HPV and the willingness of young adolescent students to be vaccinated against cervical cancer.

show abstract

Should we provide anti‐human papillomavirus vaccination for patients with genital hidradenitis suppurativa?

Nikkels

Lebas

2018

Br J Dermatol

View full text Add to dashboard Cite

DEAR EDITOR, Hidradenitis suppurativa (HS) is a not uncommon, highly debilitating inflammatory skin disease of unknown origin, particularly affecting the large folds and the anogenital area. 1 One of the most severe complications of long-standing HS is the occurrence of spindle cell carcinoma (SpCC) at the border of ulcerated HS lesions, also termed Marjolin ulcer, which occurs in up to 3Á2% of patients with HS. 2 This complication is most often seen in male patients, and more typically in the anogenital region. 2 The recognition of SpCC in these HS lesions is often delayed. Locoregional metastases are common, as well as multiple lesions with aggressive growth patterns (Fig. 1). A lethal outcome of this complication is not at all rare. 2 Patients with HS often simultaneously present several risk factors for the development of SpCC. Firstly, cigarette smoking, observed in 80-90% of patients with HS, constitutes a risk factor, both for HS and for SpCC, probably by creating a proinflammatory environment. 1 Secondly, immunosuppressive therapies, systemic steroids, ciclosporin and, more recently, tumour necrosis factor (TNF) antagonists like adalimumab, used to treat HS, may constitute other risk factors. 1 Studies have shown that in some patient categories the use of TNF antagonists increases up to twofold the risk of developing SpCC and may shorten the time to the development of nonmelanoma skin cancer, particularly in patients with psoriasis. 1 Thirdly, chronic cutaneous wounds constitute a favourable situation for developing SpCC. 2 Fourthly, oncogenic human papillomavirus (HPV)16 infection has been demonstrated in patients with genital HS and in HS-associated SpCC. 3 Finally, awareness among doctors concerning HS is insufficient, even less so for HS-associated SpCC, explaining a delay in diagnosis. 1 The bivalent (HPV 16,18), quadrivalent (HPV 6, 11, 16 and 18) and, more recently, nonavalent (6, 11, 16, 18, 31, 33, 45, 52 and 58) anti-HPV vaccinations target multiple HPV serotypes. Anti-HPV vaccination has proven efficacious with an acceptable benefit-risk profile in preventing cervical cancer and anogenital intraepithelial neoplasia. 4 In a real-life setting, the fight against obesity and smoking in patients with HS remains a difficult challenge. Hence, in the light of these data, should we not at least consider anti-HPV vaccination as a booster effect for our (male?)(smoking?) patients with genital HS? This should probably be as early as possible after disease onset, due to the long time interval between HPV infection and the actual cancer development. References1 Vekic DA, Frew J, Cains GD. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1. Australas J Dermatol 2018; 59:267-77. 2 Yuan JT, Naik HB. Complications of hidradenitis suppurativa. Semin Cutan Med Surg 2017; 36:79-85. 3 Segura Palacios JM, Garc ıa Montero P, F unez Li ebana R, Repiso Jim enez JB. Human papilloma virus and the risk of squamous cell carcinoma arising in hidradenitis suppurativa. Actas Dermosifiliog...

show abstract

Safety of HPV vaccines in the age of nonavalent vaccination

Cited by 6 publications

References 0 publications

A survey of knowledge, attitudes and awareness of the HPV and HPV vaccine among obstetricians and gynecologists across Poland

A survey of knowledge, attitudes and awareness of the HPV and HPV vaccine among obstetricians and gynecologists across Poland

The Effect of Health Education on Adolescents’ Awareness of HPV Infections and Attitudes towards HPV Vaccination in Greece

Should we provide anti‐human papillomavirus vaccination for patients with genital hidradenitis suppurativa?

Contact Info

Product

Resources

About